EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC
October 18, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable ...Leggi tutto